Symmetry Partners LLC Sells 751 Shares of CVS Health Corporation $CVS

Symmetry Partners LLC trimmed its position in CVS Health Corporation (NYSE:CVS) by 11.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,685 shares of the pharmacy operator’s stock after selling 751 shares during the quarter. Symmetry Partners LLC’s holdings in CVS Health were worth $392,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Essex Financial Services Inc. grew its holdings in CVS Health by 0.8% in the first quarter. Essex Financial Services Inc. now owns 20,705 shares of the pharmacy operator’s stock worth $1,403,000 after purchasing an additional 166 shares during the period. Williams Financial LLC raised its position in CVS Health by 2.5% in the second quarter. Williams Financial LLC now owns 6,923 shares of the pharmacy operator’s stock worth $478,000 after acquiring an additional 167 shares during the period. Hemington Wealth Management raised its position in shares of CVS Health by 33.7% during the 1st quarter. Hemington Wealth Management now owns 682 shares of the pharmacy operator’s stock valued at $46,000 after purchasing an additional 172 shares during the period. Sumitomo Life Insurance Co. raised its position in shares of CVS Health by 1.0% during the 1st quarter. Sumitomo Life Insurance Co. now owns 17,114 shares of the pharmacy operator’s stock valued at $1,159,000 after purchasing an additional 174 shares during the period. Finally, Koshinski Asset Management Inc. increased its holdings in CVS Health by 3.7% in the 1st quarter. Koshinski Asset Management Inc. now owns 4,930 shares of the pharmacy operator’s stock valued at $334,000 after acquiring an additional 178 shares during the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Stock Up 1.6%

CVS stock opened at $75.80 on Friday. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.74. The company has a market capitalization of $96.14 billion, a P/E ratio of 21.17, a PEG ratio of 0.84 and a beta of 0.62. CVS Health Corporation has a twelve month low of $43.56 and a twelve month high of $77.34. The firm has a 50 day simple moving average of $69.13 and a 200-day simple moving average of $66.99.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.35. The business had revenue of $98.92 billion for the quarter, compared to analysts’ expectations of $94.87 billion. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The company’s revenue was up 8.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.83 earnings per share. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts predict that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Thursday, October 23rd will be given a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 3.5%. The ex-dividend date of this dividend is Thursday, October 23rd. CVS Health’s dividend payout ratio (DPR) is 74.30%.

Analysts Set New Price Targets

CVS has been the subject of several research reports. Sanford C. Bernstein boosted their price objective on shares of CVS Health from $72.00 to $77.00 and gave the company a “market perform” rating in a research report on Friday, September 5th. Bernstein Bank lowered their price target on shares of CVS Health from $78.00 to $72.00 and set a “market perform” rating on the stock in a report on Wednesday, July 16th. Robert W. Baird upgraded shares of CVS Health from a “neutral” rating to an “outperform” rating and increased their target price for the company from $71.00 to $82.00 in a research report on Thursday, August 14th. Wolfe Research increased their target price on shares of CVS Health from $80.00 to $85.00 and gave the stock an “outperform” rating in a research note on Monday, September 22nd. Finally, Barclays raised their price objective on shares of CVS Health from $80.00 to $87.00 and gave the company an “overweight” rating in a research note on Thursday, September 4th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $78.25.

Insider Buying and Selling at CVS Health

In related news, Director Anne A. Finucane sold 7,500 shares of CVS Health stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total value of $532,650.00. Following the completion of the sale, the director directly owned 22,156 shares in the company, valued at $1,573,519.12. This trade represents a 25.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.22% of the company’s stock.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.